Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Universal CAR-T Cells (REVO-UWD-01) for Metastatic Colorectal Cancer
NCT06653010Phase 1Suspended
- Sponsor
- Wondercel Therapeutics
- Start
- Oct 2024
- Primary completion
- Oct 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of REVO-UWD-01 in colorectal cancer (metastatic) (mCRC), sponsored by Wondercel Therapeutics. Primary endpoints: Maximum Tolerated Dose at 1 month, Dose-Limiting Toxicities at 1 month and 1 more. Started Oct 2024; status: suspended.
02
Drugs
REVO-UWD-01
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT06653010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06653010.